Record Earnings, 8% Drop. Is the Market Reading Teradyne Right?
Damnang
· Damnang’s Substack
· April 29, 2026 at 07:20
· ⏱ 7 min read
| Read on Substack ↗
Summary
Teradyne's record Q1 2026 earnings and 87% revenue growth were overshadowed by Q2 guidance of sequential decline and concurrent AI revenue concerns from OpenAI, causing an 8.7% drop. The article argues that despite the near-term selling, Teradyne may be transitioning from a cyclical ATE stock to a structural AI test bottleneck, as rising chip complexity makes test coverage more critical over time.
•Teradyne Q1 2026 revenue was $1.282B, up 87% YoY, with non-GAAP EPS of $2.56 beating $2.11 consensus by 21%.
•CEO stated ~70% of Q1 revenue was tied to AI demand.
•Q2 guidance midpoint of $1.2B implies a sequential decline from Q1, triggering an 8.7% after-hours drop and a 5.4% regular-session decline.
•The stock had already risen over 400% in the prior year and nearly doubled YTD, making it sensitive to any hint of a peak.
•On the same day, WSJ reported OpenAI missing revenue targets, adding to selling pressure across AI infrastructure names (SoftBank, Oracle, CoreWeave, AMD, Nvidia).
•The article contrasts a cyclical 'one-time burst' view with a structural 'test bottleneck' thesis, citing HBM4 wafer sort win as a turning point that could make test demand more persistent.
Author argues that Teradyne's test equipment becomes more critical as AI chips get bigger and more complex, shifting from cyclical ATE to structural test infrastructure. The recent drop may be a valua
Author argues that Teradyne's test equipment becomes more critical as AI chips get bigger and more complex, shifting from cyclical ATE to structural test infrastructure. The recent drop may be a valuation reset rather than a cycle peak, potentially offering a long-term opportunity if the structural thesis holds.
Risk: Cyclical downturn or digestion period if AI capex slows; Q2 guidance suggests near-term peak, and the stock's high valuation amplifies downside risk.